Semax Research Notes
Selected PubMed sources, evidence limits, and current BioPep USA catalog and documentation status for Semax. Research use only.
Research-use-only scope: This article organizes published sources and BioPep USA records. It does not provide preparation, dosing, injection, human-use, animal-use, therapeutic, diagnostic, cosmetic, or clinical guidance.
Semax publications describe an ACTH(4-10) analogue in gene-expression, binding, and isolated-neuron experiments.
Questions covered by the selected literature
- Which neurotrophin transcripts were measured after experimental ischemia
- How binding and protein-level observations were studied in rats
- What isolated-neuron current measurements can establish
Evidence limits
The selected papers use animal or isolated-neuron models. They do not establish an approved human-use indication.
A paper should be read according to its own model, methods, controls, and endpoints. Cell, animal, analytical, review, and human records are not interchangeable.
Selected PubMed sources
- Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.. Cell Mol Neurobiol. 2010 Jan. PMID: 19633950.
- Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.. J Neurochem. 2006 Apr. PMID: 16635254.
- Modulation of GABA- and Glycine-Activated Ionic Currents with Semax in Isolated Cerebral Neurons.. Bull Exp Biol Med. 2018 Mar. PMID: 29577196.
BioPep USA record
BioPep USA currently lists Semax. Use the product page for current options and the documentation page for lot records.
Last reviewed: July 20, 2026.
